Global Antibody Drug Conjugates Market Report and Forecast 2024-2032

Global Antibody Drug Conjugates Market Outlook

The global antibody drug conjugates market size was valued at USD 7.96 billion in 2023, driven by the increasing awareness among government and realizing the potential of antibody drug conjugates across the globe. The market size is anticipated to grow at a CAGR of 17.1% during the forecast period of 2024-2032 to achieve a value of USD 32.97 billion by 2032.

Antibody Drug Conjugates: Introduction

Antibody-drug conjugates are a cutting-edge therapeutic approach that combines the distinct, high specificity, properties, and anti-tumour activity of monoclonal antibodies (mAbs), which are tumour-specific but insufficiently cytotoxic, with the potent cell-killing activity of highly cytotoxic small molecules that are inappropriate for systemic administration alone. Because these compounds have the ability to deliver highly cytotoxic payloads directly to tumour cells, they can be employed to achieve great lethality towards the targeted cancer cells while sparing healthy cells.

A new form of extremely powerful biopharmaceutical medication known as an "antibody-drug conjugate," or ADC, consists of an antibody coupled to a biologically active drug or cytotoxic substance via a chemical linker. These targeted medicines combine the particular and acute targeting characteristics of antibodies, enabling sensitive differentiation between healthy and cancer tissues with the cell-killing ability of cytotoxic drugs.

Global Antibody Drug Conjugates Market Analysis

The market for antibody drug conjugates has been witnessing significant growth and is expected to keep growing in the coming years as well due to various trends going on in the market currently. Antibody drug conjugates are used in the treatment of cancer but there are some attempts that have been made to expand the application of ADCs to different diseases such as atherosclerosis, bacteremia, and inflammatory diseases. The research to expand the applications is currently in progress and soon will be releasing outcomes, further expected to fuel the market growth.

LegoChem Biosciences is the key player in the market and is a major ADC developer with 25 drug candidates in development, expected to further drive the market growth. Despite, most of its pipeline assets are in the preclinical phase. The most advanced drug by LegoChem Biosciences is in Phase II clinical trials. With the most advanced portfolio, Seagen has five launched products and seven clinical-stage candidates, propelling the global antibody drug conjugates market growth.

Pfizer has announced a major investment of USD 43 billion in cash to acquire ADC pioneer Seagen Inc. The US big pharma was pulled towards four of the approved products of Seagen’s, out of which three ADCs and a small-molecule cancer drug along with other candidates in its pipeline. The expected annual revenue generated out of this purchase is USD 10bn by 2030, further propelling the market growth.

Chief Executive Officer at ImmunoGen, Inc. Enyedy exhibited the company’s partnership with MacroGenics, Inc. The collaborating companies are co-developing IMGC936 as a first-in-class ADAM9-targeting ADC. ADAM9 is a cell surface protein from the ADAM (a disintegrin and metalloproteinase) family of proteases, which has been implicated in cytokine and growth factor shedding and cell migration. It has been shown that ADAM9 is overexpressed in multiple solid tumor types (eg, non-small cell lung cancer, gastric, pancreatic, triple-negative breast and colorectal) and minimally expressed on normal tissue. IMGC936 is being tested in Phase I studies, contributing to the antibody drug conjugates market growth.

Additionally, BioNTech SE has also made and important announcement regarding exclusive license and collaboration agreements with DualityBio for two antibody-drug conjugate assets to develop and commercialize globally (excluding some Asian markets). DualityBio is expected to receive USD 170m, as well as potential development, regulatory and commercial milestone payments for both assets, totaling more than USD 1.5 billion, expected to further escalate the market expansion.

Global Antibody Drug Conjugates Market Segmentations

Market Breakup by Product Type

• Adcetris

• Kadcyla

• Other Product Types

Market Breakup by Applications

• Blood Cancer

• Breast Cancer

• Ovary Cancer

• Lung Cancer

• Skin Cancer

• Brain Tumour

• Other Application

Market Breakup by Target Type

• CD30 Antibodies

• HER2 Antibodies

• Other Target Types

Market Breakup by End User

• Hospitals and Specialty Cancer Centers

• Biotechnology and Pharmaceutical Companies

• Other End Users

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Antibody Drug Conjugates Market Overview

The market is experiencing significant market growth due to the increasing prevalence of cancer among people globally. The rising incidence of breast cancer worldwide is also contributing to the market growth. The major factors responsible for the growth of the antibody-drug conjugates market include the increasing geriatric population along with the rising research and development activities for the development of innovative treatments. Antibody-drug conjugates are believed to provide the most effective treatments to cancer patients. The lifetime probability of being diagnosed with invasive cancer is slightly higher for men (40.9%) than for women. Higher risk in men for most cancer types is thought to largely reflect greater exposure to carcinogenic environmental and behavioural factors, such as smoking, consuming alcohol, among other factors.

Geographically, North America has the highest cases of cancer, and the increasing number of cancer cases is contributing to the market growth in the region. The presence of some key players of the market aiding the antibody drug conjugates market share in the region.

In total, there will be approximately 1,958,310 new cancer cases, the equivalent of about 5370 cases each day. In addition, there will be about 55,720 new cases of ductal carcinoma in situ in women and 89,070 new cases of melanoma in situ of the skin, further increasing the demand for antibody drug conjugates.

Antibody Drug Conjugates Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Seagen Inc.

• ImmunoGen Inc. 

• Mersana Therapeutics Inc. 

• Pfizer Inc. 

• F. Hoffmann-La Roche Ltd 

• Sorrento Therapeutics Inc. 

• Oxford BioTherapeutics Ltd 

• AbbVie Inc. 

• Takeda Pharmaceutical Company Ltd 

• AstraZeneca PLC

Key Highlights of the Report